Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results

05/03/2013 | 08:40am US/Eastern
Conference Call Scheduled for May 9, 2013 at 4:30 pm ET

SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the first quarter ended March 31, 2013, after the market closes on Thursday, May 9, 2013, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial (866) 318-8616 (U.S.) or (617) 399-5135 (International); participant passcode: 65838569.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning May 9, 2013 at 6:30 p.m. ET (3:30 p.m. PT) until May 16, 2013, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 23471504. A replay of the webcast will also be accessible on the Investor Relations website for one month, through June 9, 2013.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral, extended-release formulation of various strengths of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER. Zogenix's second investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia; an investigational new drug application was submitted to the FDA in May 2012. For additional information, please visit www.zogenix.com.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Caitlin Cox | The Ruth Group
         646.536.7033 | ccox@theruthgroup.com
Zogenix
distributed by
Latest news
Date Title
<1m ago OMNICARE : Reports Third-Quarter 2014 Financial Results; Company Updates Full-Year 2014 Guidance
1m ago ELECTROMAGNETIC GEOSERVICES ASA : Spot the difference at SEG Denver 2014
1m ago STANDARD LIFE : Additional Listing
1m ago ANOTO : announces the prospectus for the issuance of new share...
2m ago AARON : S INC : Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits (form 8-K)
2m ago Manitou Q3 2014 Sales revenues
2m ago PROCTER & GAMBLE : P&G misses Street 1Q forecasts
2m ago LEAR : beats 3Q profit forecasts
2m ago OMNICARE : Reports Third-Quarter 2014 Financial Results; Company Updates Full-Year 2014 Guidance
4m ago ELITE PHARMACEUTICALS : Announces New Management Appointments
Latest news
Advertisement
Hot News 
4IMPRINT : Full Year Expectations Underpinned By Strong Third Quarter
CABELAS : Cabela's® Announces Plans for Two New Stores
STERLING ENERGY : Swings to Quarterly Loss as Oil Output Drops
MORGAN SINDALL : Issues Profit Warning On Construction Contract Woes
YELP INC : Yelp Inc. Falls after Missing Estimates; Cocrystal Pharma, Inc. Develops Ebola Screening Technology
Most Read News
1d ago AMAZON : took $170 million charge in Q3 on phone inventory, supplier costs
1d ago JUNIPER NETWORKS : AMC Networks buys 49.9 percent stake in BBC America
1d ago LOCKHEED MARTIN : Exclusive: Lockheed, Pentagon reach $4 billion deal for more F-35 jets
1d ago Microsoft sales beat Street hopes, cloud profits up
6h ago PFIZER : authorises share repurchase
Most recommended articles
4m ago Jilted Shire raises guidance again after third-quarter earnings jump
10m ago USDOLLAR Breaks October Downtrend, GBP’s GDP Rally Fizzles
10m agoDJASIA MARKETS : Japanese Stocks Snap Losing Streak
11m ago Hikma Pharma shares slip on FDA warning for Portugal plant
12m ago Ford profit beats Street; sales down on F-150 launch
Dynamic quotes  
ON
| OFF